The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 women aged 18-40 years undergoing IVF or ICSI. 3 The trial compared the efficacy and safety of follitropin delta ...

Ferring Pharmaceuticals officially opened doors to its state-of-the-art gene therapy manufacturing facility in Parsippany ...

Pierre-Yves Berclaz, Chief Science and Medical Officer at Ferring Pharmaceuticals, stated: "The ADAPT-1 trial results confirm the efficacy and safety of follitropin delta across the full range of ...

Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/day of follitropin alfa for ovarian stimulation in ...

Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta Data presented today at the ESHRE congress builds evidence for conventional-based Follicular Stimulating Hormone (FSH) dosing ...

Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta Business Wire Jul 2, 2025 ...

PARIS, July 02, 2025--Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/day of follitropin alfa for ...

The FDA has approved a new, twice-yearly PrEP injection from pharmaceutical giant Gilead. The drug is lenacapavir. The twice-yearly formulation has the brand name Yeztugo. Phase 3 trials showed ...

Many patients with adrenal insufficiency or their caregivers cannot administer emergency glucocorticoid injections, resulting in severe outcomes, suggesting the need for management and education.

Medicare may cover epidural steroid injections for pain management when the pain is severe, caused by specific conditions, and lasts over 4 weeks despite other treatment.

Cancer patients should seek medical advice before using weight-loss injections, a leading UK charity has said. Macmillan Cancer Support urged patients not to view these drugs as “quick fixes ...